



## Curriculum Vitae

**Date:** \_\_\_\_\_

\_\_\_\_\_  
**Clio Armitage Harper III, M.D.**

Austin Retina Associates, 801 W. 38<sup>th</sup> St., Suite 300 Austin, TX 78705  
Austin Retina Associates, 1545 Round Rock Avenue, Round Rock, TX 78681

### **Education**

M.D., University of Oklahoma, Oklahoma City, OK 1984 – 1988  
B.A., Molecular Biology. Vanderbilt University, *Cum Laude*, Nashville, TN 1979 - 1983

### **Postdoctoral Training**

Fellowship in Retina and Vitreous, Casey Eye Institute, Oregon Health Sciences University, Portland, OR 1993 – 1995  
Residency in Ophthalmology, Louisiana State University Eye Center, New Orleans, LA 1989 – 1993  
Internal Medicine Internship, Louisiana State University - Charity Hospital of New Orleans Internal Medicine, New Orleans, LA 1988 – 1989

### **Academic and Leadership Appointments**

Reviewer, Practicing Ophthalmologists Advisory Committee for Education (POACE) 2022 - current  
Reviewer, Clinical and Experimental Ophthalmology 2020 – current  
Reviewer, Clinical Ophthalmology 2020 – current  
Reviewer, Journal of Neonatal-Perinatal Medicine 2019 – current  
Reviewer, Journal of Ophthalmology 2019 – current  
Reviewer, Journal of Vitreoretinal Diseases 2019 – current

Examiner, American Board of Ophthalmology	2018 – current
Affiliate Faculty, Department of Ophthalmology, University of Texas Dell Medical School at Austin	2018 – current
Reviewer, AAPOS	2018 – current
Senior Advisory Board, DMS Dept. of Ophthalmology and Mitchell and Shannon Wong Eye Institute	2018 – current
Search Committee Member, Department of Ophthalmology, UT Dell Medical School at Austin	2017
Chief of Ophthalmology, Ascension Hospital System, Austin, Texas	2016 – current
Reviewer, Ophthalmic Surgery Lasers and Imaging Retina	2016 – current
Reviewer, PLOS ONE Scientific Journal	2016 – current
Ophthalmology Representative for Surgery Departmental Council, University of Texas Dell Medical School at Austin	2016 – 2018
Clinical Assistant Professor of Surgery and Perioperative Care, University of Texas Dell Medical School at Austin	2016 – 2018
Clinical Specialist of Ophthalmology; Head of ROP, University of Texas San Antonio - Department of Ophthalmology, San Antonio, TX	2012 – current
Chief of Ophthalmology, Brackenridge Hospital, Austin, TX President of Austin Ophthalmological Society	1999 – 2001
Clinical Assistant Professor, Oregon Health Sciences University, Casey Eye Institute, Portland, OR	1993 – 1995
Chief Resident Louisiana State University Eye Center, New Orleans, LA	1992 – 1993

**Other Relevant Employment and Clinical Activities**

Austin Retina Associates, Austin, TX	1995 – current
American Board of Ophthalmology Certification	1994, 2005, 2014, 2023

**Honors and Awards**

Austin Monthly “Top Doctors” Award	2023
Super Doctors Legacy Member Hall of Fame	2019
<i>Austin Monthly “Top Doctors” Award</i>	2018
<i>Texas Monthly “Super Doctor” Award</i>	2003 – current
Louisiana State University Award for Basic Science Research Project	1992
Louisiana State University Book Award for Medical Excellence	1991
University of Oklahoma – Tulsa Dean’s Award	1988
University of Oklahoma Foundation Award	1988

University of Oklahoma Glass-Nelson Scholarship	1987
B.A. in Molecular Biology <i>Cum Laude</i> , Vanderbilt Univ.	1983
Molecular Biology Honor Society	1981
Latin Honor Society	1979

**Professional Memberships and Activities with Leadership Positions**

Super Doctors Blue Ribbon Panel	2018
US Retina, member	2015 – current
Pediatric Retina Society	2014 – current
Third Coast Retina Club: 2012, 2013, 2014, 2015, 2016, 2017 meeting	2012 – current
American Society of Retina Specialists	1995 – current
Texas Ophthalmological Association	1995 – current
Austin Ophthalmological Society	1995 – current
Travis County Medical Society	1995 – current
American Academy of Ophthalmology	1989 – current

**Development of Curricula and Education Materials**

Practicing Ophthalmologists Advisory Committee for Education (POACE)	2023 – current
Telluride Retina Film Festival, co-chair and founder, Telluride, CO	2018 – current
Third Coast Retina Club CME course, program co-chair and founder, Austin, Texas	2013 – current

**Advising and Mentoring at Austin Retina Associates (Austin, TX)**

**Students**

Name, program, role, current position	
Mackenzie Franklin, Yale Undergraduate, Summer internship. Current Role: Medical Student	2015
Edward Wood, MD, Brackenridge Hospital Resident, Clinical Educator Current role: Vitreoretinal Surgeon, Associate at Austin Retina Associates	2014
Mary Kelly Green, MD, Brackenridge Transitional Internship Current Role: Ophthalmologist, Marble Falls, Texas	2005

**Other Active Research Activities and Clinical and Quality Improvement**

**Projects**

RegenXBio Inc. “Atmosphere” RGX-314-2104: Efficacy and safety of RGX-314 gene therapy in participants with neovascular wet age-related macular degeneration.	2022 – current
Genentech Inc. “Belvedere” ML43000: Safety and efficacy of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.	2022 – current
Eyepoint Pharmaceuticals Inc. “Yutiq” Eye-2102-001: Intravitreal 0.05mg fluocinolone acetonide insert in subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.	2022 – current
Genentech Inc. “GAllegole” GR42558: Intravitreal injections of FHTR2163 in patients with geographic atrophy secondary to age-related macular degeneration.	2022 – current

Regeneron Pharmaceuticals Inc. “ButterflEYE” VGFT-ROP-1920: Intravitreal aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity.	2022 – current
La Roche AG “Rhone-X” GR41987: Long-term safety and tolerability of faricimab in patients with diabetic macular edema.	2021 – current
La Roche AG “Avonelle-X” GR42691: Long-term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration.	2021 – current
Novartis Pharmaceuticals Inc. “Condor” CRTH258D2301: Efficacy and safety of brolocizumab compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy.	2021 – current
	2021 – current

Eyepoint Pharmaceuticals Inc. “Davio” Eye-1901-001: Dose escalation of tyrosine kinase inhibitor EYP-1901 in subjects with wet age-related macular degeneration.	2021 – current
Iveric Bio. “Gather2” ISEE2008: Intravitreal Zimura in patients with geographic atrophy secondary to dry age-related macular degeneration.	2021 – current
La Roche AG “Portal” GR40549: Safety and tolerability of the port delivery system with ranibizumab in patient with neovascular age-related macular degeneration.	2021
Regeneron Pharmaceuticals Inc. “Photon” VGFTe(HD)-DME-1934: High dose aflibercept in patients with diabetic macular edema.	2020 – current
Adverum Biotechnologies Inc. “Infinity” ADVM-022-04: A phase 2 clinical trial investigating the study of ADVM-022 in subjects with diabetic macular edema.	2020 – current
La Roche AG “Pagoda” GR405550: Efficacy, safety and pharmacokinetics of the port delivery system with ranibizumab in patients with diabetic macular edema.	2020 – current
Bayer AG. “Pulsar” 20968: High dose aflibercept in patients with neovascular age-related macular degeneration.	2020 – current
Kodiak Sciences, Inc. “Gleam” KS301P104: Intravitreal KSI-301 vs intravitreal aflibercept in patients with treatment naive diabetic macular edema.	2019 – current
Kodiak Sciences, Inc. “Glimmer” KS301P105: Intravitreal KSI-301 vs intravitreal aflibercept in patients with treatment naive diabetic macular edema.	2020 – current
Kodiak Sciences, Inc. “Beacon” KS301P103: Intravitreal KSI-301 vs intravitreal aflibercept for treatment naive edema secondary to retinal vein occlusion.	2020 – current
F. Hoffman-La Roche, Ltd. “Pavilion” GR41675: Port delivery system with ranibizumab in patients with diabetic retinopathy.	2020 – current
Novartis Pharmaceuticals “Talon” CRTH258A2303: Brolucizumab 6mg vs Aflibercept 2mg in patients with neovascular age-related macular degeneration.	2020 – current
Novo Nordisk A/S “Focus” NN9535-4352: Subcutaneous semaglutide vs placebo for diabetic eye disease in people with type 2 diabetes.	2020 – current
Regeneron Pharmaceuticals “Candela” VGFTe(HD)-AMD-1905: Repeated doses of high-dose aflibercept in patients with neovascular age-related macular degeneration.	2019 – current
Revolution Medicines, Inc. “Revolution” RMC-4630-01: Dose escalation of RMC-4630 monotherapy in adult participants with relapsed or refractory solid tumors.	2019 – current
Kodiak Sciences, Inc. “Dazzle” KSI-CL-102: KSI-301 administered at 12, 16, and 20 week intervals, compared with aflibercept once every 8 weeks, in participants with neovascular age-related macular degeneration.	2019 – current
Genentech Inc. “GAllego” GR40973: Intravitreal injections of RO7171009 in patients with geographic atrophy secondary to age-related macular degeneration.	2019 – current
Santen Inc. “Lumina” 010906IN: DE-109 440 every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye.	2019 – current
Novartis Pharmaceuticals “Kingfisher” CRTH258B2305: Brolucizumab 6mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in neovascular AMD patients with retinal fluid despite frequent anti-vascular endothelial growth factor injections.	2019 – current

F. Hoffmann-La Roche. Ltd. “Lucerne” GR40844: Faricimab in patients with neovascular age-related macular degeneration.	2019 – current
Ionis Pharmaceuticals “Golden” ISIS696844-CS5: IONIS-FB-LRx on the rate of change of the area of geographic atrophy secondary to age-related macular degeneration measured by fundus autofluorescence.	2019 – current
Aerie Pharmaceuticals “Orion” AR-1105-CS-201: Dexamethasone implant for the treatment of macular edema due to retinal vein occlusion.	2019 – current
Graybug Vision, Inc. “Altissimo” GBV-102-002: IVT injections of 3 dose levels of GB-102 compared with aflibercept.	2019 – current
Oregon Health & Science University “pROPer”: Partnership for understanding Retinopathy of Prematurity in the Real World. Principal investigator.	2019 – current
Novartis Pharmaceuticals “Merlin” CRTH258AUS04: Brolucizumab 6 mg q4 weeks compared to aflibercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration with persistent retinal fluid.	2019 – 2021
Chengdu Kanghong “Panda” KHB-1802: Intravitreal conbercept in patients with neovascular age-related macular degeneration.	2019 – 2021
Genentech “Archway” GR40548: Port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.	2019 – 2020
Opthea Limited “Opthea DME” OPT-302-1003: Intravitreal OPT-302 with aflibercept for persistent diabetic macular edema.	2019 – 2020
Xbrane Biopharma “Xplore” XBRANE: Xlucane vs lucentis in patients with neovascular age-related macular degeneration.	2019 – 2021
Novartis Pharmaceuticals “Kestrel” RTH258B2301: Brolucizumab vs aflibercept in patients with macular edema.	2018 – 2019
F. Hoffman-La Roche, Ltd., “Rhine” GR40398: Faricimab (RO6867461) in patients with diabetic macular edema.	2018 – 2019
Allergan Plc. “Maple” 1771-201-008: Abicipar for patients with neovascular age related macular degeneration.	2018 – 2019
Samsung Bioepis Co. Ltd. “Samsung” SB11-G31-AMD: Ranibizumab biosimilar vs lucentis in subjects with neovascular age-related macular degeneration.	2018 – 2019
Clearside Biomedical “Topaz” CLS1003-302: Suprachoroidal triamcinolone acetonide with IVT anti-VEGF in subjects with macular edema following retinal vein occlusion.	2018 – 2019
Opthea Limited OPT-302-1002: Intravitreal OPT-302 in combination with Ranibizumab vs Ranibizumab alone in patients with neovascular age-related macular degeneration.	2018 – 2019
Ophthotech Corporation OPH2005: Intravitreal anti-C5 aptamer zimura vs sham in patients with Stargardt.	2018 – 2019
Clearside Biomedical “Sapphire” CLS1003-301: Suprachoroidal triamcinolone acetonide with intravitreal aflibercept vs sham suprachoroidal procedure with intravitreal aflibercept in retinal vein occlusion with macular edema.	2017 – 2019
Clearside Biomedical “Tybee” CLS1004-201: Suprachoroidal triamcinalone acetonide with intravitreal aflibercept vs sham SC procedure with intravitreal Aflibercept for diabetic macular edema.	2017 – 2019

Ophthotech Corporation OPH2003: Intravitreal anti-C5 aptamer zimura vs sham in patients with current geographic atrophy secondary to dry age-related macular degeneration.	2017 – 2019
Eyegate Pharmaceuticals EGP-437-006: Iontopheretic dexamethasone phosphate vs prednisolone acetate suspension for treatment of non-infectious anterior segment uveitis.	2017 – 2018
Novartis Pharmaceuticals “Rainbow” Extension CRFB002H2301E1: Ranibizumab vs. laser in patients with retinopathy of prematurity. Principle Investigator.	2017 – current
Novartis Pharmaceuticals “Rainbow” CRFB002H2301: Ranibizumab vs laser in patients with retinopathy of prematurity. Principle Investigator.	2016 – current
Clearside Pharmaceuticals “Peachtree” CLS1001-301: Suprachoroidal triamcinalone acetonide injection with sham SC procedure for posterior uveitis with cystoid macular edema.	2016 – 2019
Regeneron “Panorama” VGFTe-OD-1411: Aflibercept vs sham in patients with treatment naïve with diabetic macular edema.	2016 – 2019
La Roche AG “Yosemite” GR40349: Faricimab (R06867461) vs ranibizumab in previously treated patients with diabetic macular edema.	2016 – 2017
Allergan Plc. “Beacon” 190342-038: Brimonidine intravitreal implant in geographic atrophy secondary to age-related macular degeneration.	2015 – 2018
Regeneron AMD-1417 R2176-2 vs. Eylea in patients with treatment naive CNV	2015 - current
Allegro: Pacific: Phase 2 PVD-202 Luminate (ALG1001) vs. BSS to induce PVD in patients with NPDR w/o DME	2015 – current
Allergan 150998-006 Abicipar vs. Lucentis in patients with treatment naive CNV	2015 – 2017
Roche BP29647 RO6867461 vs. Ranibizumab in patients with treatment naive CNV	2015 – current
Alcon AG “Hawk” RTH258-C001: Brolocizumab vs. aflibercept for neovascular AMD	2015 – 2018
Allegro: Del Mar: Phase 2 Luminate (ALG1001) vs. Avastin vs. laser in patients with DME	2015 – 2017
Roche GX29176 Lampalizumab in patients with Geographic Atrophy	2014 – current
Allergan 150998-004 Abicipar vs. Ranibizumab in patients with DME	2014 – 2016
Ophthotech OPH1002, Lucentis and or Fovista in patients with treatment of naive Wet AMD	2014 – current
Santen 32-007 Intravitreal DE-109 in Non-infectious Uveitis	2011 – 2016
Aerpio, AKB-9778 in patients with DME	2014 – 2015
L-Path, iSONEP sonpevizumab [LT1009] in patients with Wet AMD	2012 – 2015
iCo Therapeutics, iCo-007 (antisense DNA targeting c-raf kinase mRNA) vs Ranibizumab in patients with DME	2012 – 2014
Regeneron VGFT-OD -1009 Intravitreal VEGF Trap in DME	2011 – 2014
Allergan DEX PS DDS vs Ranibizumab in patients with DME	2012 – 2014

Allergan AGN_208397 dose escalation for patients with ME in RVO	2011 – 2013
Genentech Inc. FVF4967g Ranibizumab dosing regimen for vein occlusion	2011 – 2013
Genentech Inc. FVF4579g .5mg vs 2mg Ranibizumab in patients with Wet AMD	2011 – 2014
Glaxo Smith Kline, Pazopanib eye drops vs Ranibizumab in patients with Wet ARMD	2009 – 2012
Genentech Inc. - FVF4170g Ranibizumab vs Sham in patients with DME	2007 – 2013
Thrombogenics Microplasmin IVT in patients with VMT	2009 – 2010
Acucela, ACU-4429 oral pills in the treatment of Dry AMD	2008 – 2010
Genentech Inc. - Ranibizumab vs Sham in patients with BRVO	2008 – 2010
Genentech Inc. - Ranibizumab vs Sham in patients with CRVO	2008 – 2010
Regeneron-OD-0605 VEGF Trap in Wet AMD	2007 – 2011
Allergan 206207-019 DDS in patients with Wet AMD	2009 – 2010
Allergan 206207-018 DDS in patients with DME post vitrectomy	2009 – 2011
Alimera- Fluocinolone intravitreal vs Sham in DME	2007 – 2011
OPKO-Bevasiranib vs Lucentis in Wet AMD	2008 – 2009
Allergan, Inc. - AGN211745 vs current standard therapy in CNV	2007 – 2009
Eyeteck Inc. / Pfizer Macugen to maintain stable CNV in Wet AMD	2006 – 2008
JAEB - DRCR Observation of DME following Scatter Laser	2006 – 2008
Alcon Research, Ltd. BSS Irrigating Solution in Vitrectomy	2006 – 2007
Alcon Research, Ltd. NGOIS compared to BSS for use during surgery for ERM with Vitrectomy	2006 – 2007
Genentech - Lucentis for Wet AMD, Dose-Ranging	2005 – 2008
Genentech - Lucentis for Wet AMD, Dose-Ranging	2005 – 2006
Genentech - Lucentis extension Study for patients with AMD	2005 – 2008
Allergan - Dexamethasone vs Sham in DME	2005 – 2014
Allergan - Dexamethasone vs Sham in CRVO/BRVO	2004 – 2007
JAEB - DRCR - Triamcinolone with Laser in DME	2004 – 2006
Inspire, Denufosol in RRD	2004 – 2006
Alcon Research, Ltd. Retaane vs. Placebo in Wet AMD Risk Reduction	2004 – 2008
JAEB - DRCR Modified Laser in Diabetic Macular Edema	2004 – 2007
Genentech, Inc. rhuFab V2 in Minimally Classic CNV	2003 – 2006



Genentech, Inc. rhuFab V2 in Mostly Occult CNV	2003 – 2006
Alcon Research, Ltd - Anecortave Acetate in Predominantly Classic CNV	2002 – 2005
Clinical investigation of silicone oil for repair of retinal detachments, Co-principal investigator	1993 – 1995
Collaborative Ocular Melanoma Study	1993 – current
N.E.I. Participating Nursery Study Center for Cryotherapy for ROP	1993 – 1994

## Technology Development

### Devices / Software Applications

Development of low cost oxygen blender for neonatal intensive care units, University of Texas – Department of Biomedical Engineering.	2015 – current
---	----------------

## Publications

### Peer Reviewed Publications

1. Christa Soekamto, Luca Rosignoli, **C. Armitage Harper III**. Intravitreal Injections for Pediatric Retinal Diseases. *Springer Nature Pediatric Vitreoretinal Surgery*. 2023. [https://doi.org/10.1007/978-3-301-14506-6\\_11](https://doi.org/10.1007/978-3-301-14506-6_11)
2. Sarah H. Rodriguez, Anna L. Ells, Michael P. Blair, Parag K. Shah, **C. Armitage Harper III**, Maria Ana Martinez-Castellanos, S. Grace Prakalapakorn, Erima Denis, Rebecca C. Lusobya, Mark J. Greenwald, Sherwin J. Isenberg, Scott R. Lambert, Yvonne E. Vaucher, Ann Carroll, Lucy Namakula. Retinopathy of Prematurity in the 21<sup>st</sup> Century and the Complex of Supplemental Oxygen. *Journal of Clinical Medicine*. 2023. <https://doi.org/10.3390/jcm12031228>.
3. Nimesh A. Patel, Luis A. Acaba-Berrocal, Sandra Hoyek, **C. Armitage Harper III**, Audina M. Berrocal. Practice Patterns and Outcomes of Intravitreal Anti-VEGF Injection for Retinopathy of Prematurity. *Ophthalmology*. July 18 2022. <https://doi.org/10.1016/j.ophtha.2022.07.009>.
4. Ian D. Danford, Brittni A. Scruggs, Antonio Capone, Michael T. Trese, Kim A. Drenser, Aristomenis Thanos, Eric Nudleman, Atchara Amphornphruet, Boontip Tipsuriyaporn, G. Baker Hubbard, Anna Ells, **C Armitage Harper**, Jessica Goldstein, Charles Calvo, Chris Wallace-Carrete, Duncan Berry, Emmanuel Chang, Lisa Leishman, Michael Shapiro, Michael Blair, Mikel Mikhail, Carol L. Shields, Rachel Schwendeman, Yoshihiro Yonekawa, Mrinali P. Gupta, Anton Orlin, Supalert Prakhunhungsit, Shizuo Mukai, Audina Berrocal, M. Elizabeth Hartnett, J. Peter Campbell. The Prevalence of Retinal Disease and Associated Central Nervous System Disease in Young Patients with Incontinentia Pigmenti. *Ophthalmology Retina*. 2022. <https://doi.org/10.1016/j.oret.2022.05.032>.
5. Edward H. Wood, Antonio Capone Jr., Kimberly A. Drenser, Audinal Berrocal, G. Baker Hubbard, Natalia F. Callaway, Andres Kychenthal, Anna Ells, **Clio A. Harper III**, Cagri Giray Besirli, Caroline R. Baumal, Demetrios G. Vavvas, Emmanuel Y. Chang, Eric D. Nudleman, Irena Tsui, Jonathan Sears, Lejla Vajzovic, Mary E. Hartnett, Michael J. Shapiro, Polly A. Quiram, Sengul Ozdek, Shunjil Kusaka, Wei-Chi Wu, and Michael T. Trese. Referable Macular Hemorrhage—A Clinically Meaningful Screening Target in Newborn Infants. Position Statement of the Association of Pediatric Retina Surgeons. *Ophthalmic Surgery, Lasers & Imaging Retina*. 2022; 53:3-6. <https://doi.org/10.3928/23258160-20211214-01>

6. Kirby Taylor, Layla Ghergherehchi, Prethy Rao, **C. Armitage Harper III**, Emmanuel Chang. Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report. *Journal of American Association for Pediatric Ophthalmology and Strabismus*. 2021 May, 6  
<https://doi.org/10.1016/j.jaapos.2021.02.004>.
7. Edward H Wood, **Clio Armitage Harper III**. Maximizing the Safety of Neonatal Intravitreal Injections. *Retinal Physician*, Volume: 18. Issue: March 2021, page(s):32, 34
8. Edward H Wood, Emmanuel Y Chang, Kinley Beck, Brandon R Hadfield, Amy R Quinn, **C. Armitage Harper III**. 80 Years of Vision: Preventing Blindness from Retinopathy of Prematurity. *Journal of Perinatology* (2021). <https://doi.org/10.1038/s41372-021-01015-8>
9. Homer Chiang, Emmanuel Chang, **C. Armitage Harper III**. Retinal Detachment Repair with Perfluoro-N-octane Endotamponade in an Infant with Juvenile X-Linked Retinoschisis. *American Journal of Ophthalmology Case Reports* 2020 December; 20: 100975
10. Elizabeth J.Rossin, Irena Tsui, Sui Chien Wong, Kirk K. Hou, Supalert Prakhunhungsit, Michael P.Blair, Michael J.Shapiro, Lisa Leishman, Aaron Nagiel, Jacob A.Lifton, Polly Quiram, Alexander L. Ringeisen, Robert H Henderson, Natalia Arruti, Dominic M.Buzzacco, Shunji Kusaka, Philip J Ferrone, Peter J. Belin, Emmanuel Chang, Jean-Pierre Hubschman, Timothy G Murray, Ella H Leung, Wei-Chi Wu, Karl R. Olsen, **C. Armitage Harper III**, Safa Rahmani, Jessica Goldstein, Thomas Lee, Eric Nudleman, Linda A. Cernichiaro-Espinosa, Jay Chhablani, Audina M. Berrocal, Yoshihiro Yonekawa. Traumatic Retinal Detachment in Patients with Self-Injurious Behavior: An International Multicenter Study. *Ophthalmology Retina* 2020 Nov 22; S2468-6530(20)30463-2.
11. Kinley D Beck, Effie Z Rahman, Anna Ells, Kamiar Mireskandari, Audina M Berrocal, **C Armitage Harper 3rd**. SAFER-ROP: Updated Protocol for Anti-VEGF Injections for Retinopathy of Prematurity *Ophthalmic Surg Lasers Imaging Retina* 2020 Jul 1;51(7):402-406.
12. Abdualrahman E Hamad, Omar Moinuddin, Michael P Blair, Sidney A Schechet, Michael J Shapiro, Polly A Quiram, Danny A Mammo, Audina M Berrocal, Supalert Prakhunhungsit, Linda A Cernichiaro-Espinosa, Shizuo Mukai, Yoshihiro Yonekawa, Cindy Ung, Eric R Holz, **C Armitage Harper 3rd**, Ryan C Young, Cagri G Besirli, Aaron Nagiel, Thomas C Lee, Mrinali P Gupta, Mark K Walsh, Joseph A Khawly, J Peter Campbell, Andres Kychenthal, Eric D Nudleman, Josh E Robinson, Mary Elizabeth Hartnett, Charles M Calvo, Emmanuel Y Chang. Late-Onset Retinal Findings and Complications in Untreated Retinopathy of Prematurity *Ophthalmol Retina*. 2020 Jun;4(6):602-612
13. Jose Agustin Martinez, Pooja D Parikh, Robert W Wong, **Clio A Harper**, James W Dooner, Mark Levitan, Peter A Nixon, Ryan C Young, Shelley Day Ghafoori. Telemedicine for Diabetic Retinopathy Screening in an Urban, Insured Population Using Fundus Cameras in a Primary Care Office Setting. *Ophthalmic Surgery, Lasers & Imaging Retina* 2019 November 1, 50 (11): e274-e277
14. O'Brien P, Young RC, Ghafoori SD, **Harper CA III**, Wong RW. Central Serous Retinopathy Associated with Topical Oral Corticosteroid Use: A Case Report. *Journal of Medical Case Reports* 2019 July 2; 13(1):201
15. Elwood KF, Pulido JS, Ghafoori SD, **Harper CA III**, Wong RW. Choroidal Neovascularization and Chorioretinal Atrophy in a Patient with Melanoma-Associated Retinopathy After Ipilimumab/Nivolumab Combination Therapy. *Retinal Cases & Brief Reports* 2019 June, 00:1-5

16. **Harper CA III**, Wright LM, Young RC, Read SP, Chang EY. Fluorescein Angiographic Evaluation of Peripheral Retina Vasculature After Primary Intravitreal Ranibizumab for Retinopathy of Prematurity. *Retina*. 2019 April, Vol 39: Issue 4, Pg 700-705
17. Jeng-Miller KW, Soomro T, Scott NL, Rao P, Marlow E, Chang EY, Ells A, Chau F, Nudleman E, Calvo CM, Patel N, Schwartz R, Cernichiaro-Espinosa LA, Montoya AG, Goldstein J, **Harper CA III**, Baupal CR, Hartnett ME, Harbour JW, Besirli CG, Gupta MP, Chan RVP, Drenser KA, Capone A Jr, Murray TG, Mukai S, Trese MT, Berrocal AM, Wong SC, Yonekawa Y. Longitudinal Examination of Fellow-Eye Vascular Anomalies in Coats' Disease With Widefield Fluorescein Angiography: A Multicenter Study. *Ophthalmic Surgery, Lasers and Imaging Retina*. 2019 April, Vol 50: Issue 4, Pg 221-227
18. Parikh P, Day Ghafoori S, Dixit L, **Harper CA III**. Spontaneous Closure of a Macular Hole Resulting from YAG Laser Capsulotomy in a 13-Year-Old Girl. *Retinal Cases and Brief Reports* 2019 March, 00:1-3
19. Beck K, Young R, Read S, Harper H, Desireddi J, **Harper CA III**. The Severity and Associated Comorbidities of Retinopathy of Prematurity Among Micro-Premature Infants with Birth Weights Less Than 750 Grams. *Journal of Neonatal-Perinatal Medicine* 2019;12(1):41-45
20. Beck KD, Wong RW, Gibson JB, **Harper CA III**. Nonleaking Cystoid Macular Edema in Cohen Syndrome. *JAAPOS*, 2019 February, Volume 23, Issue 1, Pages 38–39.e1
21. Wright LM, **Harper CA III**, Change EY. Management of Infantile and Childhood Retinopathies: Optimized Pediatric Pars Plana Vitrectomy Sclerotomy Nomogram. *Ophthalmology Retina* 2018 December, Volume 2, Issue 12, Pages 1227-1234
22. Cernichiaro-Espinosa LA, **Harper CA III**, Read SP, Wright LM, Scribbick FW III, Young R, Negron CI, Rodríguez A, Berrocal AM. Report of Safety of the Use of a Short 32G Needle for Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Retinopathy of Prematurity: A Multicenter Study. *Retina*. 2018 June, Volume 38: Issue 6, Pg 1251–1255
23. Furst, M, Somogyi, MB, Wong, RW, Araujo, D, **Harper CA III**. Tamoxifen Retinopathy Treatment of an Inoperable Desmoid Tumor. *Retinal Cases and Brief Reports*. 2017, Vol. 0:1-3
24. Benson, M., Wong, RW, Young, RC, Gibson, JB, Yuxin, F, **Harper CA III**. Dynamic Retina Vessel Color Change During Ocular Compression in Severe Lipemia Retinalis. *Retinal Cases & Brief Reports*. 2017, Vol. 12: Number 4, Pg. S98-S101,
25. Jansen, M., Gaeraymovych, E., **Harper CA III**. A Metallic Intraocular Foreign Body in a Young Man. *American Academy of Ophthalmology* 2017 August, Vol. 124, Number 8, Pg. 1125
26. Fernandez, MP, Berrocal, AM, Ghabassi, MP, **Harper CA III**, Chou, E, Michael, SK, Helman, J, Sander, RD; Histopathologic Characterization of the Expression of Vascular Endothelial Growth Factor in a Case of Retinopathy of Prematurity Treated with Ranibizumab. *American Journal of Ophthalmology* 2017 April, Vol. 176, Pgs. 134-140
27. Wright, LM, Vreck, LM, Scribbick, FW, Chang, EY, **Harper CA III**; Technique for Infant Intravitreal Injection in Treatment of Retinopathy of Prematurity. *Retina, The Journal of Retinal and Vitreous Diseases*. 2017 March Vol. 37, Number 11, Pgs. 2188-2190
28. Day, S, Rainey, A.M., **Harper CA III**; Incomplete Retinal Vascularization After Ranibizumab Treatment of Retinopathy of Prematurity. *OSLI Retina*, 2017 January, Volume 48-Issue 1:75-78.

29. Day S, Martinez JA, Nixon PA, Levitan M, Dooner JW, Wong RW, **Harper CA III**. Intravitreal sulfur hexafluoride injection for the treatment of vitreomacular traction syndrome. *Retina*. 2016 September, 733-737.
30. Akinfenwa PY, Chevez-Barrios P, **Harper CA III**, Gombos D; Late presentation of Retinoblastoma in a teen with Aicardi Syndrome. *Ocular Oncology and Pathology*, 2016 April; 2(3): 181-184.
31. Beck K.D. **Harper CA III**: “Bilateral Optic Nerve Colobomas in Infants with Tetraploidy” *Ophthalmic Communications Society*, 2015
32. **Harper CA III**. 30038498: Clinical outcomes after anti-vascular endothelial Collaborative Study Group growth factor therapy for pre-threshold retinopathy of prematurity. The results of the International Anti-VEGF treatment for ROP *American Academy of Ophthalmology*, 2014
33. **Harper CA III**. Validity of a Telemedicine System for the Evaluation of Acute-Phase Retinopathy of Prematurity *JAMA Ophthalmology*, 2014 June
34. Peyman GA, Nelson NC Jr, Alturki W, Blinder KJ, Paris CL, Desai UR, **CA Harper III**. “Tissue plasminogen activation Factor assisted removal of subretinal hemorrhage” *Ophthalmic Surg*. 1993;24:575-582, 1993
35. Peyman GA, Nelson NC Jr, Alturki W, Blinder KJ, Paris CL, Desai UR, **CA Harper III**. “Perfluorocarbon liquid in traumatic vitreous hemorrhage and retinal detachment” *Ophthalmic Surg*. 1993;24:573-541
36. **Harper CA III**, Khoobehi B, Peyman GA, Gebhardt BM, Dunlap WA. “Bioavailability of microsphere entrapped Cyclosporin A in the cornea and aqueous of rabbits” *Internal Ophthalmology*, 1993
37. **Harper CA III**, Haines J. Subclavian steal syndrome: Two case studies. *Postgrad Med*, 1988
38. Nelson C, Haines JD Jr, **Harper CA III**; Gout presenting as a popliteal cyst: A case of pseudothrombophlebitis. *Postgrad Med* 1987;82(1):73-74

**Book Chapters and Publications**

“Non-Accidental Trauma,” *A Quick Guide to Pediatric Retina*. K. Tran MD, et al. Pg 283-295. Corresponding Author: **CA Harper III MD**. 2022

**Invited presentations, posters & abstracts**

**Harper CA III**. “Stopping Infant Blindness in Africa (SIBA) in Nigeria.” Vanderbilt Eye Institute. Nashville, TN. 2023

**Harper CA III**. “Vitreoretinal management in Non-Accidental Trauma (NAT).” Vanderbilt Eye Institute. Nashville, TN. 2023

**Harper CA III**. “Stopping Infant Blindness in Africa (SIBA) in Nigeria.” Third Coast Retina Conference. Austin, TX 2023

**Harper CA III**. “Oxygen: Elixir of Life – and Death.” MedNax Pediatric Grand Rounds Webinar: Diagnosis, Evolution, and Management of ROP.” Austin, TX 2023

2022

<b>Harper CA III.</b> “Oxygen: Elixir of Life – and Death.” Venezuela LXIX Congress of Ophthalmology. Caracas, Venezuela	2022
<b>Harper CA III.</b> “SAFER Technique for Injection of Anti-VEGF for ROP.” Venezuela LXIX Congress of Ophthalmology. Caracas, Venezuela	2022
<b>Harper CA III.</b> “Oxygen: Elixir of Life – and Death.” Mexican Retinal Association XLI Annual Meeting. Acapulco, Mexico	2022
<b>Harper CA III.</b> “SAFER Technique for Injection of Anti-VEGF for ROP.” Mexican Retinal Association XLI Annual Meeting. Acapulco, Mexico	2022
<b>Harper CA III.</b> “Vitreoretinal Management in Non-Accidental Trauma (NAT).” Mexican Retinal Association XLI Annual Meeting. Acapulco, Mexico	2022
<b>Harper CA III.</b> “SAFER Technique for the Injection of Anti-VEGF for ROP.” 5 <sup>th</sup> ROP World Conference. Dubai, UAE	2022
<b>Harper CA III.</b> “Practical Pearls: Laser Versus Intravitreal Injection for Retinopathy of Prematurity” 5 <sup>th</sup> ROP World Conference. Dubai, UAE	2022
<b>Harper CA III.</b> “80 Years of Vision”. Vanderbilt School of Medicine. Nashville, TN	
<b>Harper CA III, et al.</b> “Practice Patterns and Outcomes of Intravitreal Injections for Retinopathy of Prematurity – A Multicenter Study” AAO 2021 – New Orleans, LA	2021
<b>Harper CA III.</b> “Blindness from Retinopathy of Prematurity: We Can Stop It Before It Starts” 2019 Instituto Mexicano de Oftalmología – Grand Rounds, Querétaro, Mexico	2019
<b>Harper CA III.</b> “Vitreoretinal Management in Non-Accidental Trauma” 2019 Advances in Pediatric Retina Course, Salt Lake City, Utah	2019
<b>Harper CA III.</b> “80 Years of Vision” Mednax Neo: The Conference for Neonatology, Orlando, Florida	2019
<b>Harper CA III.</b> “Vitreoretinal Management in Non-Accidental Trauma” Mitchel and Shannon Wong Eye Institute and the Dept of Ophthalmology – Community Grand Rounds	2018
<b>Harper CA III.</b> “SAFER Technique for the Injection of Anti-VEGF for ROP” 2018 ROP Hot Topics. Chicago, IL	2018
<b>Harper CA III,</b> “80 Years of Vision: An Evidence Based Approach for the Treatment of ROP”. Innovations Conference. Houston, TX	2018
<b>Harper CA III.</b> “Anti-VEGF Treatment for ROP – Medications, Techniques, Tips and Tricks”. The IPOSC ROP Africa Symposium. Capetown, Africa	2018
<b>Harper CA III, Mintz-Hittner, H.</b> “ROP Treatment Roundtable: Avastin vs Lucentis”. Innovations in Neonatal Care Conference. Houston, TX	2018
<b>Harper CA III.</b> “ORBIS Experience Peru”. Third Coast Retina Meeting. Austin, TX	
<b>Harper CA III.</b> “Surgical Approach to Non-Accidental Trauma”. Association of Pediatric Retina Surgeons Meeting. Los Cabos, MX	2018

<b>Harper CA III.</b> “Surgical Approach to Non-Accidental Trauma”. Telluride Retina Film Festival. Mountain, Springs, CO	2018
Day Ghafoori S, Martinez JA, Nixon PA, Levitan M, Dooner JW, Wong RW, Young RC, <b>Harper CA III.</b> “Adherence to recommend hydroxychloroquine dosing guidelines in a private practice setting”. Dell Medical School at the University of Texas at Austin. Austin, TX	2018
Young RC, Read SP, Harper HC, <b>Harper CA III.</b> “The Severity and Associated Comorbidities of Retinopathy of Prematurity Among Micro-Premature Infants with Birth Weight Less Than 750 grams”. American Society of Retinal Specialists. Boston, MA	2017
Apple D, <b>Harper CA III,</b> Lin X, Hu J, Sumison S, Shah S, Quiram P. “Comparison of Systemic Vascular Endothelial Growth Factor After Intravitreal Injection of Ranibizumab or Laser Photocoagulation for Treatment of Retinopathy of Prematurity”. American Society of Retinal Specialists. Boston, MA	2017
<b>Harper CA III.</b> “Disruptive Technology”. 5 <sup>th</sup> Annual Third Coast Retina Club, Austin, TX	2017
Hartnett ME, <b>Harper CA III,</b> Amphonphruet A, Caputo G, Kychenthal A, Moshfeghi DM, Nudleman E, Trese MT. “Putting It All Together; Challenging Cases”. Advances in Pediatric Retina (APR) Course. Duke Eye Center, Durham, NC.	2017
<b>Harper, CA III.</b> “Current Treatment for Retinopathy of Prematurity” Dell Medical School at the University of Texas at Austin. Austin, Texas	2017
<b>Harper CA III,</b> Lobo AM. “Additional Considerations in Pediatric Retina” Advances in Pediatric Retina (APR) Course. Duke Eye Center, Durham, NC.	2017
<b>Harper CA III.</b> “Fluorescein Angiographic Findings in ROP After Lucentis Injections” American Society of Retina Specialists. San Francisco, CA.	2016
<b>Harper, CA III.</b> “Hunting for a Diagnosis”: Unknown Case Presentation: Pediatric Retina Society. Cabo San Lucas, Mexico	
Franklin M, Day S, Martinez JA, Wong RW, <b>Harper CA,</b> Levitan ML, Dooner JW, Nixon PA. Survey of Patient Utilization of Web-Based Health Data Management Technology in an Outpatient Retina Practice Setting. 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Seattle, WA.	2016
<b>Harper CA.</b> Unknown Case Presentation. 4th Annual Third Coast Retina Club, Dallas, TX	2016
<b>Harper CA.</b> “Age Related Macular Degeneration;” “Pediatric Ocular Trauma”, University of Texas Health Science Center, Retina Day, San Antonio, TX	2014
<b>Harper CA.</b> “Incontinentia Pigmenti” Pediatric Retina Society, Cabo San Lucas, Mexico	2014
<b>Harper CA.</b> “ROP Treatment and Results” 3rd Annual Third Coast Retina Club	2014
<b>Harper CA.</b> “Neonatal Ophthalmology” University of Texas Health Science Center San Antonio, San Antonio, TX	2013
<b>Harper CA.</b> “Incontinentia Pigmenti” 2nd Annual Third Coast Retina Club	2013
<b>Harper CA.</b> “Approach to Retinopathy of Prematurity” Austin, TX	2013
<b>Harper CA.</b> “Practical Approach to Retinopathy of Prematurity” Austin, TX	2013

<b>Harper CA.</b> “The China-Haiti Experience” Austin Ophthalmological Society, Austin, TX	2012
<b>Harper CA.</b> “Wide Field Imaging Symposium” Round Rock, TX	2012
<b>Harper CA.</b> “Practical Approach to Retinopathy of Prematurity” San Antonio, TX	2012
<b>Harper CA.</b> “Practical Approach to Retinopathy of Prematurity” Austin, TX	2012
<b>Harper CA.</b> “Current Therapy for ROP” Austin, TX	2012
<b>Harper CA.</b> “Practical Approach to Retinopathy of Prematurity” Austin, TX	2012
<b>Harper CA.</b> “Practical Approach to Retinopathy of Prematurity” San Antonio, TX	2011
<b>Harper CA.</b> “Retina Sub-Specialty Session” JCAHPO Annual Continuing Education Program, Chicago, IL	2010
<b>Harper CA.</b> “Current and Emerging Treatment Options for AMD” JCAHPO Annual Continuing Education Program, Chicago, IL	2010
<b>Harper CA.</b> “Retina and Imaging Symposium” JCAHPO Retina TechTrax, Improving Patient Care for Retinal Neovascular Disease, Memphis, TN	2010
<b>Harper CA.</b> “Retina and Imaging Symposium” JCAHPO Retina TechTrax, Improving Patient Care for Retinal Neovascular Disease, Los Angeles, CA	2010
<b>Harper CA.</b> “Practical Approach to Retinopathy of Prematurity” University of Texas at San Antonio	2010
<b>Harper CA.</b> “Practical Approach to Retinopathy of Prematurity” American Academy of Ophthalmology, Retina Pre-Academy, San Francisco, CA	2009
<b>Harper CA.</b> “Sewn-In Posterior Chamber Intraocular Lenses” Casey Eye Institute/Oregon Health Sciences Univ. Columbia Gorge. Update: Retina, Cornea/Contact Lens.	1994
<b>Harper CA.</b> “Nutrition and AMD- Update on the Use of Vitamins and Minerals.” Casey Institute/Oregon Health Sciences Univ. AMD Workshop	1994
<b>Harper CA.</b> “Ocular Manifestations of sexually transmitted disease” Invited lecturer, LSU Department of Internal Medicine	1992
<b>Harper CA.</b> “Bioavailability of Microsphere-entrapped Cyclosporine A in the cornea and aqueous of rabbits.” ARVO	1992
<b>Harper CA.</b> “The use of Vitreon in the removal of massive vitreous hemorrhage caused by perforating ocular trauma” ARVO	1992
<b>Harper CA.</b> Prevention of hypertensive kidney disease in blacks: Ophthalmologic indicator. A pilot study. NIH Grant application	1991
<b>Harper CA.</b> “Tissue Plasminogen Activator in the Management of Ocular Disease” Louisiana State University Resident’s Day	1991
<b>Harper CA.</b> “Gout Presenting as a Popliteal Cyst” University of Oklahoma Research Day	1989

**Community Service**

Myra S. Hymans & Carol S. Harper Memorial College Scholarship Fund, 2022 - present

Project ORBIS, Trujillo, Peru 2018

Small World Vision Non-Profit 501(c)3, Founder 2016

Vanderbilt University Eye Project, Port-au-Prince, Haiti

Project ORBIS, Lanzhou, China (2012)

<http://www.orbis.org/Default.aspx?cid=9917&lang=1>

Vanderbilt University Eye Project, Port-au-Prince, Haiti

<http://www.statesman.com/news/news/opinion/austin-doctor-experiences-haitis-spirit-and-flight/nRjXw/>

Project ORBIS, Vietnam (2017)

<http://www.orbis.org/country/vietnam>

Project ORBIS, Peru (2018)

<https://www.orbis.org/en/news/2018/flying-eye-hospital-lands-in-peru>